US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US7179892B2
(en)
*
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US6905686B1
(en)
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US6761888B1
(en)
*
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
US20030147882A1
(en)
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
ES2312348T3
(es)
|
1999-06-16 |
2009-03-01 |
Boston Biomedical Research Institute |
Control inmunologico de niveles de beta-amiloide in vivo.
|
TR200202799T3
(tr)
|
2000-02-24 |
2003-03-21 |
Washington University St.Louis |
AB peptidini sekanslayan insanlaştırılmış antikorlar
|
PE20020574A1
(es)
*
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
ES2437875T3
(es)
*
|
2001-04-30 |
2014-01-14 |
Eli Lilly And Company |
Anticuerpos humanizados que reconocen el péptido beta-amiloide
|
DE60229051D1
(de)
*
|
2001-04-30 |
2008-11-06 |
Lilly Co Eli |
Humanisierte antikörper
|
AU2002345843A1
(en)
*
|
2001-06-22 |
2003-01-08 |
Panacea Pharmaceuticals, Inc. |
Compositions and methods for preventing protein aggregation in neurodegenerative diseases
|
JP4729717B2
(ja)
†
|
2001-08-03 |
2011-07-20 |
株式会社医学生物学研究所 |
GM1ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするDNA
|
US20060073149A1
(en)
*
|
2001-08-17 |
2006-04-06 |
Bales Kelly R |
Rapid improvement of cognition in condition related to abeta
|
WO2003016466A2
(en)
*
|
2001-08-17 |
2003-02-27 |
Eli Lilly And Company |
ANTI-Aβ ANTIBODIES
|
JP4511830B2
(ja)
*
|
2001-08-17 |
2010-07-28 |
ワシントン・ユニバーシティ |
アルツハイマー病のアッセイ方法
|
WO2003016467A2
(en)
*
|
2001-08-17 |
2003-02-27 |
Eli Lilly And Company |
Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
|
DK1944040T3
(da)
*
|
2001-08-17 |
2012-10-29 |
Univ Washington |
Analysefremgangsmåde for Alzheimers sygdom
|
US7179606B2
(en)
*
|
2001-11-23 |
2007-02-20 |
Syn X Pharma, Inc. |
IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
|
MY139983A
(en)
*
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
CA2483729A1
(en)
*
|
2002-04-25 |
2003-11-06 |
Eli Lilly And Company |
Method for treating anxiety and mood disorders in older subjects
|
WO2004029629A1
(en)
*
|
2002-09-27 |
2004-04-08 |
Janssen Pharmaceutica N.V. |
N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
|
FR2846667B1
(fr)
*
|
2002-11-06 |
2004-12-31 |
Pasteur Institut |
Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
|
US20070010435A1
(en)
|
2002-12-19 |
2007-01-11 |
New York University |
Method for treating amyloid disease
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
KR20050118669A
(ko)
*
|
2003-02-01 |
2005-12-19 |
뉴랄랩 리미티드 |
가용성 a-베타에 대한 항체를 생성하기 위한 능동 면역화
|
ATE468886T1
(de)
|
2003-02-10 |
2010-06-15 |
Applied Molecular Evolution |
Abeta-bindende moleküle
|
US8663650B2
(en)
|
2003-02-21 |
2014-03-04 |
Ac Immune Sa |
Methods and compositions comprising supramolecular constructs
|
US7732162B2
(en)
|
2003-05-05 |
2010-06-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
|
TWI374893B
(en)
|
2003-05-30 |
2012-10-21 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
BRPI0411852A
(pt)
|
2003-06-27 |
2006-05-23 |
Abgenix Inc |
anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seu usos
|
KR101139103B1
(ko)
*
|
2003-09-12 |
2012-07-05 |
아피리스 아게 |
아페레시스 장치
|
AT413336B
(de)
|
2003-09-12 |
2006-02-15 |
Mattner Frank Dr |
Apherese-vorrichtung
|
US7848543B2
(en)
*
|
2004-02-05 |
2010-12-07 |
Brainlab Ag |
Method and system for prediction and management of material and information transport in an organism
|
EA009872B1
(ru)
*
|
2004-02-23 |
2008-04-28 |
Эли Лилли Энд Компани |
АНТИ-Aβ АНТИТЕЛА
|
WO2005105998A1
(ja)
*
|
2004-04-27 |
2005-11-10 |
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute |
ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
|
WO2006014478A1
(en)
*
|
2004-07-02 |
2006-02-09 |
Northwestern University |
MONOLOCAL ANTIBODIES THAT TARGET PATHOLOGICAL ASSEMBLIES OF AMYLOID β (ABETA)
|
US20060024667A1
(en)
|
2004-07-29 |
2006-02-02 |
Karen Manucharyan |
Compositions and methods for Alzheimer's disease
|
AU2005294373B2
(en)
*
|
2004-10-05 |
2011-12-08 |
Janssen Alzheimer Immunotherapy |
Methods and compositions for improving recombinant protein production
|
US9907485B2
(en)
*
|
2004-10-15 |
2018-03-06 |
Brainlab Ag |
Targeted immunization and plaque destruction against Alzheimer's disease
|
US9924888B2
(en)
*
|
2004-10-15 |
2018-03-27 |
Brainlab Ag |
Targeted infusion of agents against parkinson's disease
|
US9901413B2
(en)
*
|
2004-10-15 |
2018-02-27 |
Brainlab Ag |
Targeted infusion of agents for treatment of ALS
|
TW200636066A
(en)
*
|
2004-12-15 |
2006-10-16 |
Elan Pharm Inc |
Humanized antibodies that recognize beta amyloid peptide
|
TW200635607A
(en)
|
2004-12-15 |
2006-10-16 |
Elan Pharm Inc |
Humanized Aβ antibodies for use in improving cognition
|
PE20061401A1
(es)
*
|
2004-12-15 |
2006-12-23 |
Neuralab Ltd |
ANTICUERPOS Aß PARA MEJORAR LA COGNICION
|
WO2006069081A2
(en)
*
|
2004-12-22 |
2006-06-29 |
Washington University In St. Louis |
USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
|
WO2006081171A1
(en)
*
|
2005-01-24 |
2006-08-03 |
Amgen Inc. |
Humanized anti-amyloid antibody
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
EA015148B1
(ru)
|
2005-06-17 |
2011-06-30 |
Элан Фарма Интернэшнл Лимитед |
СПОСОБЫ ОЧИСТКИ Aβ-СВЯЗЫВАЮЩЕГО БЕЛКА, СОДЕРЖАЩЕГО ОБЛАСТЬ FC
|
AU2006319358B2
(en)
*
|
2005-11-30 |
2012-01-19 |
AbbVie Deutschland GmbH & Co. KG |
Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
|
KR101439828B1
(ko)
|
2005-11-30 |
2014-09-17 |
애브비 인코포레이티드 |
아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
|
RU2015111675A
(ru)
*
|
2005-12-12 |
2015-08-10 |
Ац Иммуне Са |
Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
|
RS52004B
(en)
|
2005-12-12 |
2012-04-30 |
F. Hoffmann-La Roche Ag |
ANTIBODIES AGAINST AMYLOID BETA WITH GLYCOSILATION IN THE VARIABLE REGION
|
EP2177536B1
(en)
*
|
2006-03-30 |
2014-06-04 |
Glaxo Group Limited |
Antibodies against amyloid-beta peptide
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
CN101058608B
(zh)
*
|
2006-04-21 |
2011-02-23 |
杜如昱 |
人类抗Aβ1-32淀粉样蛋白抗体、其纯化方法及用途
|
EP3988566A1
(en)
*
|
2006-07-14 |
2022-04-27 |
AC Immune SA |
Humanized antibody against amyloid beta
|
KR101605207B1
(ko)
*
|
2006-07-14 |
2016-03-22 |
에이씨 이뮨 에스.에이. |
아밀로이드 베타에 대해 인간화된 항체
|
RS56986B1
(sr)
*
|
2006-07-14 |
2018-05-31 |
Ac Immune Sa |
Humanizovana antitela na beta amiloid
|
KR20150002879A
(ko)
*
|
2006-10-02 |
2015-01-07 |
에이씨 이뮨 에스.에이. |
아밀로이드 베타에 대해 인간화된 항체
|
EP2076287A2
(en)
|
2006-10-12 |
2009-07-08 |
Wyeth |
Methods and compositions with reduced opalescence
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
WO2008084402A2
(en)
|
2007-01-11 |
2008-07-17 |
Philipps-Universitaet Marburg |
Diagnosis and treatment of alzheimer's and other neurodementing diseases
|
PT2842967T
(pt)
|
2007-01-18 |
2017-01-13 |
Lilly Co Eli |
Fab beta amilóide peguilado
|
EP2121633A2
(en)
|
2007-02-12 |
2009-11-25 |
Merck & Co., Inc. |
Piperazine derivatives for treatment of ad and related conditions
|
WO2008104386A2
(en)
|
2007-02-27 |
2008-09-04 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
EP2481408A3
(en)
|
2007-03-01 |
2013-01-09 |
Probiodrug AG |
New use of glutaminyl cyclase inhibitors
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
RU2523894C2
(ru)
*
|
2007-04-18 |
2014-07-27 |
Янссен Альцгеймер Иммунотерапи |
Предупреждение и лечение церебральной амилоидной ангиопатии
|
DK2142514T3
(da)
|
2007-04-18 |
2015-03-23 |
Probiodrug Ag |
Thioureaderivater som glutaminylcyclase-inhibitorer
|
CA2687330A1
(en)
|
2007-05-18 |
2008-11-27 |
The Johns Hopkins University |
A treatment simulator for brain diseases and method of use thereof
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
JP2010528583A
(ja)
*
|
2007-06-11 |
2010-08-26 |
エーシー イミューン ソシエテ アノニム |
アミロイドβに対するヒト化抗体
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
US8048420B2
(en)
|
2007-06-12 |
2011-11-01 |
Ac Immune S.A. |
Monoclonal antibody
|
CN101820911B
(zh)
*
|
2007-06-12 |
2015-05-06 |
Ac免疫有限公司 |
β淀粉样蛋白的人源化抗体
|
DK2182983T3
(da)
|
2007-07-27 |
2014-07-14 |
Janssen Alzheimer Immunotherap |
Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
|
SG188136A1
(en)
*
|
2007-09-13 |
2013-03-28 |
Delenex Therapeutics Ag |
HUMANIZED ANTIBODIES AGAINST THE ß-AMYLOYD PEPTIDE
|
NZ585110A
(en)
*
|
2007-10-05 |
2012-09-28 |
Genentech Inc |
Method and compositions for diagnosis and treatment of amyloidosis
|
EP2238166B1
(en)
|
2007-10-05 |
2013-11-27 |
Genentech, Inc. |
Use of anti-amyloid beta antibody in ocular diseases
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
ME01026B
(me)
*
|
2007-11-16 |
2012-10-20 |
Univ Rockefeller |
Antitijela specifična za protofibrilni oblik beta-amiloid proteina
|
US8414893B2
(en)
|
2007-12-21 |
2013-04-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
EP2106802A1
(en)
|
2008-04-02 |
2009-10-07 |
SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. |
Modified peptides as synthetic vaccines in amyloid-associated disease
|
EP2149380A1
(en)
*
|
2008-07-29 |
2010-02-03 |
Medivet Pharma, S.L. |
Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
|
EP2328908A4
(en)
|
2008-08-28 |
2012-11-28 |
Univ New York State Res Found |
TREATMENT OF AMYLOIDOSES BASED ON MYELIN BASED PROTEIN AND FRAGMENTS THEREOF
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
US8614297B2
(en)
|
2008-12-22 |
2013-12-24 |
Hoffmann-La Roche Inc. |
Anti-idiotype antibody against an antibody against the amyloid β peptide
|
AU2010294214B2
(en)
|
2009-09-11 |
2015-05-07 |
Vivoryon Therapeutics N.V. |
Heterocylcic derivatives as inhibitors of glutaminyl cyclase
|
MX2012006512A
(es)
|
2009-12-11 |
2012-08-17 |
Araclon Biotech Sl |
Metodos y reactivos para la deteccion mejorada de peptidos beta amiloides.
|
US9102717B2
(en)
|
2010-03-01 |
2015-08-11 |
The J. David Gladstone Institutes |
Antibody specific for apolipoprotein and methods of use thereof
|
JP6026284B2
(ja)
|
2010-03-03 |
2016-11-16 |
プロビオドルグ エージー |
グルタミニルシクラーゼの阻害剤
|
AU2011226074B2
(en)
|
2010-03-10 |
2015-01-22 |
Vivoryon Therapeutics N.V. |
Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
|
CA2796339C
(en)
|
2010-04-15 |
2020-03-31 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
EP2560953B1
(en)
|
2010-04-21 |
2016-01-06 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
WO2011149461A1
(en)
|
2010-05-27 |
2011-12-01 |
Medtronic, Inc. |
Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
|
SG187173A1
(en)
|
2010-07-30 |
2013-02-28 |
Ac Immune Sa |
Safe and functional humanized anti beta-amyloid antibody
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
EP3533803B1
(en)
|
2010-08-14 |
2021-10-27 |
AbbVie Inc. |
Anti-amyloid-beta antibodies
|
US20120237975A1
(en)
|
2010-10-01 |
2012-09-20 |
Jason Schrum |
Engineered nucleic acids and methods of use thereof
|
JP6050264B2
(ja)
|
2011-03-16 |
2016-12-21 |
プロビオドルグ エージー |
グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
|
EP2691101A2
(en)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
ES2602794T3
(es)
|
2011-03-31 |
2017-02-22 |
Pfizer Inc |
Piridinonas bicíclicas novedosas
|
EP2511296A1
(en)
|
2011-04-12 |
2012-10-17 |
Araclón Biotech, S. L. |
Antibody, kit and method for determination of amyloid peptides
|
WO2012172449A1
(en)
|
2011-06-13 |
2012-12-20 |
Pfizer Inc. |
Lactams as beta secretase inhibitors
|
EP2751116B1
(en)
|
2011-08-31 |
2016-10-12 |
Pfizer Inc |
Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
|
JP2012050437A
(ja)
*
|
2011-09-12 |
2012-03-15 |
Janssen Alzheimer Immunotherapy |
ベータアミロイドペプチドを認識するヒト化抗体
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
CA2850624A1
(en)
|
2011-10-03 |
2013-04-11 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
KR102280111B1
(ko)
|
2011-12-22 |
2021-07-21 |
에프. 호프만-라 로슈 아게 |
발현 벡터 구성, 신규한 생산 세포 생성 방법 및 폴리펩티드의 재조합 생산을 위한 그의 용도
|
CA2868398A1
(en)
|
2012-04-02 |
2013-10-10 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
ES2585262T3
(es)
|
2012-05-04 |
2016-10-04 |
Pfizer Inc |
Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
|
MD20140130A2
(ro)
|
2012-06-29 |
2015-04-30 |
Pfizer Inc. |
4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
|
BR112014033066A2
(pt)
*
|
2012-07-03 |
2017-08-01 |
Janssen Alzheimer Immunotherap |
método para tratamento de um paciente diagnosticado com doença de alzheimer, forma humanizada, quimérica ou revestida de um anticorpo, e, anticorpo.
|
EP2897964A1
(en)
|
2012-09-20 |
2015-07-29 |
Pfizer Inc. |
Alkyl-substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
|
UA110688C2
(uk)
|
2012-09-21 |
2016-01-25 |
Пфайзер Інк. |
Біциклічні піридинони
|
JP6144355B2
(ja)
|
2012-11-26 |
2017-06-07 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
化学修飾mRNA
|
CA2893256A1
(en)
|
2012-12-11 |
2014-06-19 |
Pfizer Inc. |
Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
|
EP2935282A1
(en)
|
2012-12-19 |
2015-10-28 |
Pfizer Inc. |
CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
|
EP2956458B1
(en)
|
2013-02-13 |
2017-08-09 |
Pfizer Inc |
Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
US9233981B1
(en)
|
2013-02-15 |
2016-01-12 |
Pfizer Inc. |
Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
PE20151332A1
(es)
|
2013-02-19 |
2015-09-20 |
Pfizer |
Compuestos de azabencimidazol
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP2999716A2
(en)
|
2013-05-20 |
2016-03-30 |
F. Hoffmann-La Roche AG |
Anti-transferrin receptor antibodies and methods of use
|
RU2016107435A
(ru)
|
2013-09-13 |
2017-10-18 |
Дженентек, Инк. |
Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
|
NZ756749A
(en)
|
2013-09-13 |
2022-05-27 |
Genentech Inc |
Methods and compositions comprising purified recombinant polypeptides
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
JP2016538829A
(ja)
|
2013-10-03 |
2016-12-15 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
低密度リポタンパク質受容体をコードするポリヌクレオチド
|
JP6425717B2
(ja)
|
2013-10-04 |
2018-11-21 |
ファイザー・インク |
ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン
|
CA2933767C
(en)
|
2013-12-17 |
2018-11-06 |
Pfizer Inc. |
Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
|
AP2016009465A0
(en)
|
2014-04-01 |
2016-09-30 |
Pfizer |
Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
|
EA030085B1
(ru)
|
2014-04-10 |
2018-06-29 |
Пфайзер Инк. |
2-АМИНО-6-МЕТИЛ-4,4a,5,6-ТЕТРАГИДРОПИРАНО[3,4-d][1,3]ТИАЗИН-8a(8H)-ИЛ-1,3-ТИАЗОЛ-4-ИЛ АМИДЫ
|
WO2015165961A1
(en)
|
2014-04-29 |
2015-11-05 |
Affiris Ag |
Treatment and prevention of alzheimer's disease (ad)
|
WO2016012896A1
(en)
|
2014-07-24 |
2016-01-28 |
Pfizer Inc. |
Pyrazolopyrimidine compounds
|
CN106795165B
(zh)
|
2014-08-06 |
2019-09-10 |
辉瑞公司 |
咪唑并哒嗪化合物
|
US10508151B2
(en)
|
2014-11-19 |
2019-12-17 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
EP3786182A1
(en)
|
2014-11-19 |
2021-03-03 |
Axon Neuroscience SE |
Humanized tau antibodies in alzheimer's disease
|
US11008403B2
(en)
|
2014-11-19 |
2021-05-18 |
Genentech, Inc. |
Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
|
JP6628805B2
(ja)
|
2015-02-03 |
2020-01-15 |
ファイザー・インク |
新規シクロプロパベンゾフラニルピリドピラジンジオン
|
EP3310784B1
(en)
|
2015-06-17 |
2020-10-07 |
Pfizer Inc |
Tricyclic compounds and their use as phosphodiesterase inhibitors.
|
CA2991856A1
(en)
|
2015-07-21 |
2017-01-26 |
Bioarctic Neuroscience Ab |
Method for treatment of traumatic brain injury targeting aggregated peptides
|
AU2016322813B2
(en)
|
2015-09-14 |
2021-04-01 |
Pfizer Inc. |
Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
|
JP2018534251A
(ja)
|
2015-09-24 |
2018-11-22 |
ファイザー・インク |
Bace阻害剤として有用なn−[2−(3−アミノ−2,5−ジメチル−1,1−ジオキシド−5,6−ジヒドロ−2h−1,2,4−チアジアジン−5−イル)−1,3−チアゾール−4−イル]アミド
|
JP2018531924A
(ja)
|
2015-09-24 |
2018-11-01 |
ファイザー・インク |
テトラヒドロピラノ[3,4−d][1,3]オキサジン誘導体、およびbace阻害剤としてのその使用
|
WO2017051276A1
(en)
|
2015-09-24 |
2017-03-30 |
Pfizer Inc. |
N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
EP3368563A1
(en)
|
2015-10-28 |
2018-09-05 |
The Trustees Of The University Of Pennsylvania |
Intrathecal administration of adeno-associated-viral vectors for gene therapy
|
US10774120B2
(en)
|
2015-11-09 |
2020-09-15 |
The University Of British Columbia |
Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
|
KR20180088828A
(ko)
|
2015-11-09 |
2018-08-07 |
더 유니버시티 오브 브리티쉬 콜롬비아 |
아밀로이드 베타에서의 n-말단 에피토프 및 이에 형태적으로-선택적인 항체
|
JP7452829B2
(ja)
|
2015-11-09 |
2024-03-19 |
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア |
アミロイドベータのエピトープおよびそれに対する抗体
|
KR102148587B1
(ko)
|
2016-02-23 |
2020-08-26 |
화이자 인코포레이티드 |
6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물
|
TWI798751B
(zh)
|
2016-07-01 |
2023-04-11 |
美商美國禮來大藥廠 |
抗-N3pGlu類澱粉β肽抗體及其用途
|
AU2017286868B2
(en)
|
2016-07-01 |
2021-11-11 |
Pfizer Inc. |
5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
|
WO2018031361A2
(en)
|
2016-08-09 |
2018-02-15 |
Eli Lilly And Company |
Combination therapy
|
JP2019536471A
(ja)
|
2016-09-27 |
2019-12-19 |
セロ・セラピューティクス・インコーポレイテッドCERO Therapeutics, Inc. |
キメラエンガルフメント受容体分子
|
US11124562B2
(en)
|
2016-10-28 |
2021-09-21 |
Washington University |
Anti-ApoE antibodies
|
US20180125920A1
(en)
|
2016-11-09 |
2018-05-10 |
The University Of British Columbia |
Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
|
MX2019010756A
(es)
|
2017-03-10 |
2020-01-20 |
Pfizer |
Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
|
IL269215B
(en)
|
2017-03-10 |
2022-09-01 |
Pfizer |
Disubstituted imidazole[4,5-c]quinoline derivatives
|
JOP20190247A1
(ar)
*
|
2017-04-20 |
2019-10-20 |
Lilly Co Eli |
أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
|
JP2020523035A
(ja)
|
2017-06-07 |
2020-08-06 |
エーディーアールエックス, インコーポレイテッド |
タウ凝集阻害剤
|
FI3642202T3
(fi)
|
2017-06-22 |
2023-03-01 |
|
Dihydro-pyrrolo-pyridiinijohdannaisia
|
IL271488B1
(en)
*
|
2017-06-29 |
2024-02-01 |
Univ Columbia |
Chimeric antibodies for the treatment of diseases characterized by amyloid deposition
|
CA3070085A1
(en)
|
2017-07-18 |
2019-01-24 |
Promis Neurosciences Inc. |
Antibodies to amyloid beta
|
US11382974B2
(en)
|
2017-08-01 |
2022-07-12 |
The Trustees Of Columbia University In The City Of New York |
Methods and compositions for treatment of amyloid deposition diseases
|
US11453701B2
(en)
|
2017-08-18 |
2022-09-27 |
Adrx, Inc. |
Tau aggregation peptide inhibitors
|
CA3073421A1
(en)
|
2017-09-26 |
2019-04-04 |
Daniel Mark COREY |
Chimeric engulfment receptor molecules and methods of use
|
PL3461819T3
(pl)
|
2017-09-29 |
2020-11-30 |
Probiodrug Ag |
Inhibitory cyklazy glutaminylowej
|
WO2019074840A1
(en)
*
|
2017-10-09 |
2019-04-18 |
Keith Black |
COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOID RELATED DISEASES
|
CN112154145B
(zh)
|
2018-03-23 |
2023-10-17 |
辉瑞大药厂 |
哌嗪氮杂螺衍生物
|
US20210015865A1
(en)
|
2018-03-28 |
2021-01-21 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
|
WO2019226690A1
(en)
*
|
2018-05-21 |
2019-11-28 |
New York University |
Treatment of melanoma brain metastasis by inhibition of amyloid precursor protein cleavage
|
US20220031867A1
(en)
|
2018-10-04 |
2022-02-03 |
University Of Rochester |
Glymphatic delivery by manipulating plasma osmolarity
|
EP3898667A2
(en)
|
2018-12-20 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Modified antibody fcs and methods of use
|
FR3091999A1
(fr)
*
|
2019-01-25 |
2020-07-31 |
Mexbrain |
Dispositif d’extraction conjointe d’un cation métallique et d’une molécule cible
|
EP4045641A1
(en)
|
2019-10-15 |
2022-08-24 |
Eli Lilly and Company |
Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
|
MX2023000949A
(es)
|
2020-07-23 |
2023-02-22 |
Othair Prothena Ltd |
Anticuerpos anti-beta-amiloide (abeta).
|
TW202243690A
(zh)
|
2021-01-11 |
2022-11-16 |
美商美國禮來大藥廠 |
抗N3pGlu類澱粉β抗體及其用途
|
TW202300518A
(zh)
|
2021-03-12 |
2023-01-01 |
美商美國禮來大藥廠 |
抗N3pGlu類澱粉β抗體及其用途
|
TW202300517A
(zh)
|
2021-03-12 |
2023-01-01 |
美商美國禮來大藥廠 |
抗類澱粉β抗體及其用途
|
WO2022251048A1
(en)
|
2021-05-24 |
2022-12-01 |
Eli Lilly And Company |
Anti-amyloid beta antibodies and uses thereof
|
WO2023150483A1
(en)
|
2022-02-03 |
2023-08-10 |
Eli Lilly And Company |
Regional tau imaging for diagnosing and treating alzheimer's disease
|